Merck KGaA, Darmstadt, Germany, Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology
Merck KGaA, Darmstadt, Germany, today announced that the Australian Patent Office has allowed the company’s patent application for the use of paired CRISPR nickases. 15 AUG 2018 | DARMSTADT, GERMANY Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research Expands company’s foundational CRISPR cutting and integration IP necessary to correct genetic... Read more